Show simple item record

 
dc.contributorInstitut d'Assistència Sanitària
dc.contributor.authorLouro, Javier
dc.contributor.authorRomán, Marta
dc.contributor.authorPosso, Margarita
dc.contributor.authorComerma Blesa, Laura
dc.contributor.authorSaladie, Francina
dc.contributor.authorAlcantara-Souza, Rodrigo
dc.contributor.authorSánchez, Mar
dc.contributor.authorQuintana, María Jesús
dc.contributor.authordel Riego, Javier
dc.contributor.authorFerrer, Joana
dc.contributor.authorVidal, Carmen
dc.date.accessioned2022-02-08T14:32:17Z
dc.date.available2022-02-08T14:32:17Z
dc.date.issued2020-10-03
dc.identifier.citationLouro J, Román M, Posso M, Comerma L, Vidal C, Saladié F, et al. Differences in breast cancer risk after benign breast disease by type of screening diagnosis. The Breast. 2020 Dec 1;54:343–8.
dc.identifier.issn0960-9776
dc.identifier.urihttps://hdl.handle.net/11351/6991
dc.descriptionBreast neoplasms; Early cancer detection; Risk factors
dc.description.abstractIntroduction: We aimed to assess differences in breast cancer risk across benign breast disease diagnosed at prevalent or incident screens. Materials and methods: We conducted a retrospective cohort study with data from 629,087 women participating in a long-standing population-based breast cancer screening program in Spain. Each benign breast disease was classified as non-proliferative, proliferative without atypia, or roliferative with atypia, and whether it was diagnosed in a prevalent or incident screen. We used partly conditional Cox hazard regression to estimate the adjusted hazard ratios of the risk of breast cancer. Results: Compared with women without benign breast disease, the risk of breast cancer was significantly higher (p-value ¼ 0.005) in women with benign breast disease diagnosed in an incident screen (aHR, 2.67; 95%CI: 2.24e3.19) than in those with benign breast disease diagnosed in a prevalent screen (aHR, 1.87; 95%CI: 1.57e2.24). The highest risk was found in women with a proliferative benign breast disease with atypia (aHR, 4.35; 95%CI: 2.09e9.08, and 3.35; 95%CI: 1.51e7.40 for those diagnosed at incident and prevalent screens, respectively), while the lowest was found in women with non-proliferative benign breast disease (aHR, 2.39; 95%CI: 1.95e2.93, and 1.63; 95%CI: 1.32e2.02 for those diagnosed at incident and prevalent screens, respectively). Conclusion: Our study showed that the risk of breast cancer conferred by a benign breast disease differed according to type of screen (prevalent or incident). To our knowledge, this is the first study to analyse the impact of the screening type on benign breast disease prognosis
dc.language.isoeng
dc.publisherElsevier
dc.publisherChurchill Livingstone
dc.relation.ispartofseriesThe Breast;54
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Diagnòstic
dc.subjectMama - Càncer - Factors de risc
dc.subjectMama - Malalties - Imatgeria
dc.subject.meshBreast Neoplasms
dc.subject.meshMammography
dc.subject.meshRisk Factors
dc.titleDifferences in breast cancer risk after benign breast disease by type of screening diagnosis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.breast.2020.09.005
dc.subject.decsneoplasias de la mama
dc.subject.decsmamografía
dc.subject.decsfactores de riesgo
dc.relation.publishversionhttps://doi.org/10.1016/j.breast.2020.09.005
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.event.productorBiblioteca
dc.contributor.authoraffiliation[Louro J] Hospital Del Mar Medical Research Institute (IMM), Barcelona, Spain. Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain. Servei d’Epidemiologia i Avaluació, Hospital del Mar, Barcelona, Spain. European Higher Education Area (EHEA) Doctoral Programme in Methodology of Biomedical Research and Public Health in Department of Pediatrics, Obstetrics and Gynecology, Preventive Medicine and Public Health, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Román M, Posso M] Hospital del Mar Medical Research Institute (IMM), Barcelona, Spain. Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain. Servei d’Epidemiologia i Avaluació, Hospital del Mar, Barcelona, Spain. [Comerma L] Servei de Patologia, Hospital del Mar, Barcelona, Spain. [Vidal C] Institut Català d’Oncologia (ICO), Barcelona, Spain. [Saladié F] Cancer Epidemiology and Prevention Service, Hospital Universitari Sant Joan de Reus, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Spain. [Alcándara R] Servei de Diagnòstic per la Imatge, Hospital del Mar, Barcelona, Spain. [Sánchez M] Direction General of Public Health, Cantabria, Spain. [Quintana MJ] Department of Clinical Epidemiology and Public Health, University Hospital de La Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain. CIBER of Epidemiology and Public Health (CIBERESP), Spain. [Del Riego J] Women’s Imaging, Department of Radiology, UDIAT Centre Diagnòstic, Parc Taulí Hospital Universitari, Sabadell, Spain. [Ferrer J] Radiology Department, Hospital de Santa Caterina, Institut d’Assistència Sanitària (IAS), Salt, Spain
dc.identifier.pmid33023825
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record